Rather than removing individuals taking anti-depressant medication and losing valuable genetic information, CES-D scores were adjusted for treatment effect using a similar algorithm used for adjustment of blood pressure for persons taking anti-hypertensive medications (Levy et al. 2000) . Since response to anti-depressant medication is highly variable and information on compliance to medication is not always available in population-based studies, there were two assumptions made when adjusting CES-
D scores. First, CES-D scores of anti-depressant users are right-censored. That is, the CES-D score while on anti-depressant medication is lower than the score while not taking anti-depressant medication.
Second, participants with low depressive symptoms scores respond less to anti-depressant medication than persons with high depressive symptom scores, on average.
The algorithm for adjustment of anti-depressant use was run separately for multiple factors: gender, race, and exam period, on a total of 6,438 individuals. The nonparametric imputation algorithm replaces the CES-D score of a person using anti-depressants with the mean depressive symptom score for all persons taking anti-depressants with the same or higher depressive symptom score. This method has recently been used in a large depressive symptom GWAS consortium (Hek et al. 2013) . Anti-depressant use was participants from exam 4. The distribution of CES-D in this sample is skewed right, with the majority of values being less than 10. A total of 7.6%, 7.9% and 8.1% of persons were on anti-depressant medications at exams 1, 3 and 4, respectively. We chose not to exclude participants taking anti-depressant medication as they often are individuals with depression or higher depressive symptom scores and thus add value to genetic studies.
